Indications

Prescribing Information

Next Page Icon

Medication Guide

Next Page Icon
Potential OPDIVO® (nivolumab) user watching sailboats on a lake with his grandchildren.
Potential OPDIVO® (nivolumab) user watching sailboats on a lake with his grandchildren.

Clinical trial results for
early-stage non-small
cell lung cancer
(NSCLC) before surgery

Given before surgery to adults with non-small cell lung cancer to help prevent it from returning after surgery

Actor portrayals.
OPDIVO + chemotherapy is not approved for
people younger than 18 years of age.

An FDA-approved combination of immunotherapy and chemotherapy that helped reduce the risk of cancer spreading or returning compared to platinum-based chemotherapy

Your doctor has determined having surgery will be an important step for you to take in treating your early-stage non-small cell lung cancer, but to make sure the tumor is small enough to be removed and that no hidden or hard to see cells are left, your doctor may recommend a pre-surgery treatment.

About the clinical trial

In a clinical trial of 358 people with early-stage NSCLC who were able to have surgery, 179 people were given OPDIVO + chemotherapy before surgery, and 179 people were given platinum-based chemotherapy before surgery.

People given OPDIVO + chemotherapy before surgery remained free of their cancer spreading or returning longer compared to platinum-based chemotherapy

At 32 months, half of those receiving OPDIVO® (nivolumab) + chemotherapy remained free of cancer spreading or returning.
OPDIVO + chemotherapy

Half the people remained free of cancer spreading or returning

At 21 months, half the people given platinum-based chemotherapy remained free of cancer spreading or returning.
Platinum-based chemotherapy

Half the people remained free of cancer spreading or returning

OPDIVO + chemotherapy given before surgery was proven to reduce the risk of their cancer spreading or returning by 37% compared to chemotherapy alone.

More people given OPDIVO + chemotherapy before surgery saw their tumors disappear completely after surgery compared to platinum-based chemotherapy

24% of patients given OPDIVO® (nivolumab) + chemo before surgery saw tumors disappear post-op, compared to 2% with just chemo.

OPDIVO + chemotherapy will not work for everyone. Individual results may vary.

Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

Nurse monitoring a gentleman's infusion of OPDIVO® (nivolumab) immunotherapy treatment.

Getting an infusion

See your recommended treatment plan and what to expect from an infusion

For adults with early-stage non-small cell lung cancer (NSCLC) before surgery

OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine before you have surgery for early-stage NSCLC that does not have an abnormal EGFR or ALK gene, and then may be continued alone after surgery to help prevent your lung cancer from coming back.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.



1506-US-2400468 09/24